Novel agents in the treatment of multiple myeloma: a review about the future
about
Towards Stratified Medicine in Plasma Cell MyelomaPDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.Monitoring multiple myeloma by quantification of recurrent mutations in serum.Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.How is patient care for multiple myeloma advancing?Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma.Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis.Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.New and emerging therapies for acute and chronic graft versus host disease.The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism
P2860
Q28074994-2E1D62CB-1943-4562-A300-4207ADD3AC70Q33889132-DAFD5223-2703-460F-B1BD-FFF758F401B9Q37223934-17D68893-6429-4582-A177-0015A03BB7A1Q38375161-A559AE70-0B08-416A-A6B4-AC442D3CEB24Q38609866-DDFAC5D0-0494-43AC-8E92-E9368AD7FE44Q38757067-5FEB8802-CCF4-4B4A-B811-DB630BAC5255Q38786149-B10F0FE8-BE31-4D81-AD80-CDE1900CB0ACQ39024142-0ED02E4E-EB86-4912-8D4B-4C8E271C1F55Q39113994-C7D2926C-F345-4A58-9A3A-061C23137543Q39234159-F513A5EC-07B4-4685-85DA-38D77B4EF712Q39403929-4ECD1F68-258F-450D-B8AB-B93DF5A1424EQ41169814-D7672404-64DD-4B8A-9B69-52FFF982AA22Q41396044-EDAE8ECD-1EEE-4C25-B34B-89A8E3F752A3Q47329036-3EA102EB-9580-41FC-BF39-6972225A5A91Q48143831-7E9C0924-D8AE-4F38-8D9E-CD0914F823ABQ49238507-B3FD6894-ED7C-4A49-82A3-4D9D753D308BQ50054859-F4158394-E99C-4EA5-A7F7-4FCCAE1B783CQ50129476-3F9EE792-3839-4BA7-8BBD-4C0C5FB26821Q52597827-CEAFD892-2CF5-49D5-9532-CD267FD7A668Q55140257-0E2C9A7A-9674-4F5F-95DB-AFCC10FE3511Q55392778-21D630B2-8946-4CBE-B578-9A1B8113A472Q55642634-8230EB9A-22D7-40F1-9C2F-F9F5FBFFE58EQ58780167-D7BC1E82-AD11-457B-89BF-538CB0A5B58D
P2860
Novel agents in the treatment of multiple myeloma: a review about the future
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Novel agents in the treatment of multiple myeloma: a review about the future
@ast
Novel agents in the treatment of multiple myeloma: a review about the future
@en
Novel agents in the treatment of multiple myeloma: a review about the future
@nl
type
label
Novel agents in the treatment of multiple myeloma: a review about the future
@ast
Novel agents in the treatment of multiple myeloma: a review about the future
@en
Novel agents in the treatment of multiple myeloma: a review about the future
@nl
prefLabel
Novel agents in the treatment of multiple myeloma: a review about the future
@ast
Novel agents in the treatment of multiple myeloma: a review about the future
@en
Novel agents in the treatment of multiple myeloma: a review about the future
@nl
P2860
P3181
P1476
Novel agents in the treatment of multiple myeloma: a review about the future
@en
P2093
Leonard Naymagon
P2860
P2888
P3181
P356
10.1186/S13045-016-0282-1
P407
P50
P5008
P577
2016-06-30T00:00:00Z
P6179
1036719040